Tokyo, Aug. 2 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058651) titled 'Comparison Efficacy of Cefmetazole or Flomoxef Versus Carbapenem Antibiotics for ESBL-Producing Enterobacterales Bacteremia: A Systematic Review and Meta-Analysis' on July 31.

Study Type: Others,meta-analysis etc

Primary Sponsor: Institute - Tohoku Medical and Pharmaceutical University and Tohoku Medical and Pharmaceutical University Hospital

Condition: Condition - Extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales bacteremia Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - In recent years, the number of infections caused by antimicrobial-resistant organisms have been increasing worldwide, and the number of associated deaths continues to rise annually. Treatment and infection control strategy for antimicrobial-resistant organisms is a significant public health concern. Extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales represent one of major global health problem as an antimicrobial-resistant organisms. Carbapenems is the standard treatment for these organisms infections, and there is little evidence supporting the use of alternative antimicrobial agents.

Cefmetazole and flomoxef belong to cephamycin-class antibiotics that are especially-available in Asian countries, including Japan. These agents have shown potential efficacy against bloodstream infections caused by ESBL-producing Enterobacterales, and accumulating evidence from Asia suggests their clinical utility. However, there was no randomized controlled trials, and high-quality evidence remains insufficient to support their results.

Therefore, we conducted a systematic review and meta-analysis to evaluate the efficacy of cefmetazole and flomoxef compared with carbapenems, against bloodstream infections caused by ESBL-producing Enterobacterales. Basic objectives2 - Efficacy

Eligibility: Age-lower limit - 18 years-old <= Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - We will conduct a literature search to compare 14 day or 30 day mortality, between cefmetazole or flomoxef and carbapenems for patients with ESBL-producing Enterobacterales bacteremia. Our search will be performed in the following databases: PubMed, Japanese Journal of Chemotherapy, Japanese Journal of Infection Prevention and Control, Ichushi-WEB, Cochrane Review, CINAHL, and Web of Science. Key exclusion criteria - Under 18 years old,Pregnancy,Infections caused by ESBL producing Enterobacteriaceae without bacteremia,No information about 14 day or 30 day mortality,Studies for which the full text was not accessible Target Size - 10

Recruitment Status: Recruitment status - No longer recruiting Date of protocol fixation - 2025 Year 07 Month 31 Day Date of IRB - 2025 Year 07 Month 31 Day Anticipated trial start date - 2025 Year 07 Month 31 Day Last follow-up date - 2025 Year 10 Month 30 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067073

Disclaimer: Curated by HT Syndication.